Apremilast

Patients with psoriasis or psoriatic arthritis treated with ustekinumab demonstrated a 1.4- to 3-times lower risk for hospitalization with serious infections than those who received other biologics or apremilast, according to data.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about research on deucravacitinib presented at AAD VMX 2021.

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, spoke with Healio about the results and clinical implications of the POETYK PSO-1 and POETYK PSO-2 trials.

Deucravacitinib showed significant improvement in plaque psoriasis compared with both placebo and apremilast, according to two studies presented at AAD VMX 2021.

Deucravacitinib improved psoriasis compared with placebo and apremilast in a phase 3 study, Bristol Myers Squibb announced in a press release.

Depression rates were lower in patients treated with apremilast monotherapy for psoriasis or psoriatic arthritis and higher in those treated with biologics, corticosteroids and non-apremilast combinations, according to a presentation.

Acitretin, apremilast and methotrexate can be used to treat immune checkpoint inhibitors-mediated psoriasis, according to a study published in Journal of the American Academy of Dermatology.

Treatment with apremilast alone is effective in patients with oligoarticular psoriatic arthritis, according to data published in The Journal of Rheumatology.

Apremilast improved nail psoriasis at week 36, with improvement seen as early as week 8, according to a presentation at the European Academy of Dermatology and Venerology congress.

Among patients with psoriasis who showed an inadequate response to apremilast, etanercept was associated with strong response rates and patient-reported outcomes, according to a recently published study.